Published in J Transl Med on April 07, 2006
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | NCT00501644
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
An integrative model for recurrence in ovarian cancer. Mol Cancer (2008) 0.99
Immunotherapy for ovarian cancer. Curr Treat Options Oncol (2015) 0.89
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol (2009) 0.84
IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med Chem (2013) 0.81
Effect of Mucosal Cytokine Administration on Selective Expansion of Vaginal Dendritic Cells to Support Nanoparticle Transport. Am J Reprod Immunol (2015) 0.76
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol (1993) 18.75
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell (2001) 13.24
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 8.88
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27
Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med (1998) 4.52
Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (1986) 2.84
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol (1997) 2.17
Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol (2001) 2.02
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol (2000) 1.67
Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol (2001) 1.61
Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res (2000) 1.53
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol (2004) 1.50
Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood (1998) 1.35
Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A (1985) 1.29
CD16+ and CD16- human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol (2001) 1.26
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 1.25
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer (2000) 1.17
CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord (2005) 1.13
Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res (2006) 1.13
Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol (2003) 1.13
Circulating CD2+ monocytes are dendritic cells. J Immunol (1999) 1.07
The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol (1988) 1.00
Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects. Cancer Res (1994) 0.99
A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res (1991) 0.95
Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol (1992) 0.91
Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood (2002) 0.91
Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer (2002) 0.90
GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia (1998) 0.89
Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res (1998) 0.88
Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. Int J Cancer (1995) 0.87
rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. J Transl Med (2003) 0.87
Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res (1986) 0.85
The role of cytokines in cancer. Cytokine Growth Factor Rev (1996) 0.84
Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res (1991) 0.84
Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplant (1996) 0.81
CXC chemokines mechanism of action in regulating tumor angiogenesis. Angiogenesis (1998) 0.81
Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer (2000) 0.80
Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer (2003) 0.80
Granulocyte-macrophage-colony-stimulating factor and other cytokines: as adjuncts to cancer immunotherapy, stem cell transplantation, and vaccines. Curr Hematol Rep (2004) 0.80
Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored. Curr Oncol Rep (2003) 0.79
Interferon in the treatment of ovarian cancer. Semin Oncol (1988) 0.77
Enzyme-linked immunospot assays provide a sensitive tool for detection of cytokine secretion by monocytes. Clin Diagn Lab Immunol (2001) 0.77
Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med (2008) 9.32
Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA (2004) 6.98
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol (2013) 3.04
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A (2006) 2.51
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol (2006) 2.48
Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol (2009) 2.35
Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Obstet Gynecol (2007) 2.34
Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psychooncology (2003) 2.17
Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol (2005) 2.17
Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol (2004) 2.09
Oncologists' attitudes toward and practices in giving bad news: an exploratory study. J Clin Oncol (2002) 2.04
Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer (2011) 2.02
Laparoendoscopic single-site surgery in gynecology: review of literature and available technology. J Minim Invasive Gynecol (2010) 1.86
Short-term and long-term psychosocial adjustment and quality of life in women undergoing different surgical procedures for breast cancer. Ann Surg Oncol (2007) 1.85
Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol (2012) 1.80
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol (2007) 1.80
Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol (2010) 1.77
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila) (2009) 1.75
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer (2013) 1.74
Radical hysterectomy in obese and morbidly obese women with cervical cancer. Obstet Gynecol (2008) 1.70
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol (2007) 1.69
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol (2006) 1.63
Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. Gynecol Oncol (2009) 1.62
Tuberculosis: a benign impostor. AJR Am J Roentgenol (2010) 1.62
The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys (2003) 1.60
Common cancer biomarkers. Cancer Res (2006) 1.56
Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. J Soc Integr Oncol (2010) 1.53
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2008) 1.50
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecol Oncol (2003) 1.50
Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol (2004) 1.49
Are women ready for the HPV vaccine? Gynecol Oncol (2006) 1.47
Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy? Gynecol Oncol (2010) 1.46
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer (2010) 1.46
Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. Am J Obstet Gynecol (2006) 1.45
Patterns of regional recurrence after definitive radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys (2009) 1.45
Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer (2009) 1.42
Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res (2005) 1.39
A phase III randomized clinical trial comparing laparoscopic or robotic radical hysterectomy with abdominal radical hysterectomy in patients with early stage cervical cancer. J Minim Invasive Gynecol (2008) 1.34
Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med (2005) 1.33
Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol (2013) 1.30
18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med (2009) 1.30
Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study. AJR Am J Roentgenol (2008) 1.29
Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia (2007) 1.29
Desmoid tumor of the small bowel and the mesentery. AJR Am J Roentgenol (2004) 1.28
Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol (2011) 1.28
Rate of port-site metastasis is uncommon in patients undergoing robotic surgery for gynecological malignancies. Int J Gynecol Cancer (2011) 1.28
Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res (2012) 1.25
Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center. Cancer (2010) 1.25
Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.23
Primary malignant melanoma of the vagina. Obstet Gynecol (2010) 1.22
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2006) 1.21
Integrative Oncology Practice Guidelines. J Soc Integr Oncol (2007) 1.21
Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer. Obstet Gynecol (2009) 1.21
Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol (2010) 1.20
Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol (2009) 1.18
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother (2012) 1.18
A pilot study of the effects of expressive writing on psychological and behavioral adjustment in patients enrolled in a Phase II trial of vaccine therapy for metastatic renal cell carcinoma. Health Psychol (2002) 1.17
Rate of vaginal cuff separation following laparoscopic or robotic hysterectomy. Gynecol Oncol (2010) 1.16
PET/CT of esophageal cancer: its role in clinical management. Radiographics (2007) 1.15
Trends in laparoscopic and robotic surgery among gynecologic oncologists: A survey update. Gynecol Oncol (2009) 1.14
Qigong improves quality of life in women undergoing radiotherapy for breast cancer: results of a randomized controlled trial. Cancer (2013) 1.14
Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol (2014) 1.14
Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer (2013) 1.14
Conservative management of early stage cervical cancer: is there a role for less radical surgery? Gynecol Oncol (2011) 1.13
Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res (2006) 1.13
Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res (2012) 1.11
Atypical sigmoid metastasis from a high-grade mixed adenocarcinoma of the ovary. Gynecol Oncol (2004) 1.10
The biopsy-proven benign thyroid nodule: is long-term follow-up necessary? J Am Coll Surg (2013) 1.09
Cervix regression and motion during the course of external beam chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys (2008) 1.09
Imaging in cervical cancer. Cancer (2003) 1.08
Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy - a systematic literature review. Gynecol Oncol (2013) 1.08
Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res (2005) 1.08
Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol (2008) 1.07
Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol (2010) 1.07
Has the time come for sentinel lymph node biopsy alone in radical hysterectomy patients? Gynecol Oncol (2007) 1.06
Immunohistochemical studies of trophoblastic tumors. Am J Surg Pathol (2009) 1.04
Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training. Gynecol Oncol (2004) 1.04
Conservative management of a uterine tumor resembling an ovarian sex cord-stromal tumor. Gynecol Oncol (2004) 1.04
Melanoma-restricted genes. J Transl Med (2004) 1.03
Myeloid growth factors. J Natl Compr Canc Netw (2011) 1.03
Diagnosis, staging, and surveillance of cervical carcinoma. AJR Am J Roentgenol (2003) 1.03